Published in J Chromatogr on May 01, 1978
Distribution of misonidazole in human tumours and normal tissues. Br J Cancer (1979) 1.43
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer (1980) 1.33
Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice. Br J Cancer (1979) 1.30
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents. Br J Cancer (1982) 1.16
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer (1980) 1.08
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms. Br J Cancer (1984) 0.89
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer (1982) 0.85
Chemosensitization by lipophilic nitroimidazoles. Br J Cancer (1983) 0.84
The penetration of misonidazole into spontaneous canine tumours. Br J Cancer (1979) 0.84
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer (1981) 0.83
Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse. Br J Cancer (1980) 0.83
Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients. Br J Cancer (1981) 0.81
The penetration of misonidazole into a mature structural cartilage. Br J Cancer (1982) 0.78
A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix. Br J Cancer (1982) 0.75
The effect of phenytoin, phenobarbitone, dexamethasone and flurbiprofen on misonidazole neurotoxicity in mice. Br J Cancer (1984) 0.75
The role of dexamethasone in the modification of misonidazole pharmacokinetics. Br J Cancer (1983) 0.75
Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer (1977) 5.58
Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol (1976) 3.55
Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res (1976) 3.44
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results. Br J Cancer (1975) 2.39
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer (1975) 2.02
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1996) 1.93
Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer (1977) 1.90
The sensitivity to bleomycin of a solid mouse tumour at different stages of growth. Br J Cancer (1974) 1.88
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene (1992) 1.84
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
An investigation of radioactive yttrium (90Y) for the treatment of chronic knee effusions. Br J Radiol (1970) 1.83
Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res (1978) 1.80
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol (1997) 1.68
Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer (1986) 1.66
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Hyperthermia in the treatment of cancer. Cancer Treat Rev (1979) 1.49
Final report of the general clinical results of the British Institute of Radiology fractionation study of 3F/wk versus 5F/wk in radiotherapy of carcinoma of the laryngo-pharynx. Br J Radiol (1990) 1.48
Structure-activity relationships in the development of hypoxic cell radiosensitizers. I. Sensitization efficiency. Int J Radiat Biol Relat Stud Phys Chem Med (1979) 1.47
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
Misonidazole-a drug for trial in radiotherapy and oncology. Int J Radiat Oncol Biol Phys (1979) 1.41
The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography. Br J Cancer (1992) 1.39
Trimethoprim-sulphonamide hypersensitivity in dogs. Vet Rec (1990) 1.39
The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl (1978) 1.38
Unilateral epistaxis in two dairy cows. Vet Rec (1998) 1.37
Irradiation of the synovium in the treatment of rheumatoid arthritis. Q J Med (1973) 1.35
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun (1991) 1.32
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer (1991) 1.26
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica (1978) 1.24
The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos (1985) 1.24
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol (2001) 1.24
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene (2008) 1.24
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer (1979) 1.23
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer (1996) 1.20
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
The radioimmunoassay of buprenorphine. Eur J Clin Pharmacol (1980) 1.17
Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry. Anal Chem (1976) 1.17
An analysis of error in the retrieval of patient case note data. J Laryngol Otol (1970) 1.17
Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer (1999) 1.17
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 1.16
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer (1991) 1.15
Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol Biol Phys (1986) 1.15
Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line. Cell Tissue Kinet (1975) 1.14
Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol (1981) 1.14
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
The sensitivity of cells in exponential and stationary phases of growth to bleomycin and to 1,3-bis(2-chloroethyl)-1-nitrosourea. Br J Cancer (1973) 1.13
The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer (1976) 1.12
Hypoxic cell sensitization by misonidazole in vivo and in vitro. Br J Radiol (1978) 1.12
Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer (1996) 1.12
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
Clinical studies with misonidazole. Br J Cancer Suppl (1978) 1.10
An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10
Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line. Br J Cancer (1975) 1.09
Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials (1980) 1.09
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer (1980) 1.08
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer (1989) 1.08
Radioactive yttrium in the treatment of rheumatoid knee effusions. Preliminary evaluation. Ann Rheum Dis (1971) 1.07
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer (2005) 1.07
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol (1983) 1.06
Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol (1994) 1.06
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer (1991) 1.06
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer (1977) 1.06
In vivo studies of radioactive phosphorus in malignant tumours. Clin Radiol (1967) 1.06
A metabolite of the 2-nitroimidazole misonidazole with radiosensitizing properties. Int J Radiat Biol Relat Stud Phys Chem Med (1978) 1.05
Metabolism of debrisoquine sulphate in rat, dog and man. Xenobiotica (1976) 1.04
The sensitivity to bleomycin of spleen colony forming units in the mouse. Br J Cancer (1973) 1.04
Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer (1994) 1.04
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol (1980) 1.02
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys (1982) 1.01